Treatment of chronic urticaria with omalizumab: the experience of Hospital de Braga
Introduction: Omalizumab is approved for the treatment of severe chronic spontaneous urticaria (CSU), unresponsive to quadruple doses of nonsedative H1 antihistamine. Few data are available to help predict the response to omalizumab in the Portuguese population. Objective: Characterize the populatio...
Saved in:
Main Authors: | , , , , , , |
---|---|
Format: | Bog |
Udgivet: |
Sociedade Portuguesa de Dermatologia e Venereologia,
2022-10-01T00:00:00Z.
|
Fag: | |
Online adgang: | Connect to this object online. |
Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|
Vær først til at give en kommentarø!